Eva Hausnerova, PhD
Cardiology · Chevy Chase, MDNPI 1639106172
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Among cardiology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$746
- Boehringer Ingelheim$599
- Novartis$499
- Pfizer$375
- Johnson & Johnson$327
- Amgen$181
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,446100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $746 |
| Boehringer Ingelheim | 19 | $599 |
| Novartis | 20 | $499 |
| Pfizer | 18 | $375 |
| Johnson & Johnson | 7 | $327 |
| Amgen | 4 | $181 |
| Merck | 12 | $173 |
| AstraZeneca | 5 | $173 |
| Bridgebio Pharma, Inc. | 3 | $153 |
| Abbott | 1 | $130 |
| Chiesi USA, Inc. | 1 | $130 |
| Boston Scientific | 1 | $119 |
| Alnylam Pharmaceuticals Inc. | 3 | $102 |
| Sanofi | 1 | $102 |
| Actelion Pharmaceuticals US, Inc. | 2 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| Arbor Pharmaceuticals, Inc. | 4 | $62 |
| Atricure, Inc. | 2 | $61 |
| Esperion Therapeutics, Inc. | 3 | $55 |
| Baxter Healthcare | 2 | $45 |
| Scpharmaceuticals Inc. | 2 | $35 |
| Corcept Therapeutics | 1 | $24 |
| Medtronic | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| GSK | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| CMP Pharma, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,446 in reported general payments places this provider in the 90th percentile of 44 cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $98,847 |
| EntrestoSacubitril/Valsartan | 33 | $49,419 |
| Rosuvastatin Calcium | 275 | $4,219 |
| Amiodarone Hcl | 51 | $2,363 |
| Losartan Potassium | 131 | $1,403 |
| Metoprolol Succinate | 62 | $1,330 |
| Digoxin | 64 | $1,069 |
| Olmesartan Medoxomil | 29 | $749 |
| Valsartan | 13 | $725 |
| Amlodipine Besylate | 74 | $595 |
| Furosemide | 58 | $554 |
| ClopidogrelClopidogrel Bisulfate | 29 | $430 |
| Metoprolol Tartrate | 72 | $354 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $328 |
| Levothyroxine Sodium | 18 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $375 | $98,84785 claims |
| NovartisEntresto | $499 | $49,41933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 44 cardiology providers in Maryland.
Other cardiology in Chevy Chase
- Mohammadali HabibiBaltimore$15K
- Ayim Akyea DjamsonBeltsville$11K
- Michael WilberBaltimore$5K
- Hassanali KassamaliBaltimore$4K
- John ConditEaston$3K
- Pankaj LalRockville$3K
- Timothy ShanahanEaston$3K
- Anil SinghCumberland$2K
- Fayaz ShawlTakoma Park$2K
- Ashok ChopraBaltimore$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.